The ADC field is slowly becoming the place where good chemistry goes to print money.

Enhertu has redrawn the HER2 territory in breast and gastric cancers.

Trodelvy commands billions in TROP2 territory.

The pipeline behind these is a parade of variations on the same handful of antigens, with companies racing each other to find the next ER-positive breast cancer or the next bladder indication.

Meanwhile, an entire class of tumor-specific surface markers has been sitting underexploited because they’re hard to drug.

Enter Tacalyx, the Berlin biotech going after tumor-associated carbohydrate antigens, or TACAs. Tacalyx closed an €11 million seed extension from existing investors Boehringer Ingelheim Venture Fund, Kurma Partners, and Eurazeo.

Proceeds going to push lead asset TCX-201 toward a 2027 Clinical Trial Application filing.

TCX-201 is an ADC that targets TACAs…Tumor Associated Carbohydrate Antigens.

TACAs are surface glycans – sugar chains – that decorate cancer cell surfaces but are mostly absent from differentiated healthy tissue.

They’ve been theoretically ideal targets for decades, but the problem is that glycans are notoriously hard to raise high-affinity, tumor-specific antibodies against.

They’re floppy, low-immunogenicity, and the immune system tends to ignore them.

Tacalyx came out of the Max Planck Institute of Colloids and Interfaces in Potsdam in 2019. The Max Planck team there has been one of the few groups in the world reliably generating clinical-grade anti-glycan antibodies, partly because of the institute’s deep history in carbohydrate chemistry.

The IP and the team is the platform.

They’ve now built a seven-program pipeline.

The lead indications for TCX-201 are gastrointestinal and other solid tumors, which is a good entry point because TACAs are particularly enriched on GI tumor surfaces compared to neighboring healthy gut tissue.

Those tumors have been a graveyard for HER2 and TROP2 expansions, in part because the antigens aren’t selective enough in this tissue context.

Glycan targeting offers a different selectivity argument.

Now, I think we can glean something from their funding situation.

€11 million is kind of wimpy in this space, but the fact that Boehringer’s venture arm is leading the third tranche of a seed in a 2026 funding environment, where most preclinical companies are getting cut adrift, says the biology must be robust.

And BIVC aren’t the only ones throwing down some cash.

Eurazeo and Kurma have been reliable European life science investors with patient timelines.

Tacalyx has now raised $12.1M cumulatively at a $0 valuation step you can imagine, but the asset and the platform are the long game.

The 2027 CTA filing is the gate.

If TCX-201 enters clinic on schedule and shows even modest tumor regression in a GI cancer cohort, the platform reads very differently.

Can Glycan ADCs become an entirely new category?